Halozyme to Report First Quarter 2025 Financial and Operating Results
Halozyme Therapeutics (NASDAQ: HALO) has announced it will release its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, after market close. The company will host a conference call the same day at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. Investors can access the call through pre-registration and join the live webcast through the Investors section of Halozyme's corporate website.
Halozyme Therapeutics (NASDAQ: HALO) ha annunciato che pubblicherà i risultati finanziari e operativi del primo trimestre 2025 martedì 6 maggio 2025, dopo la chiusura dei mercati. La società terrà una conference call lo stesso giorno alle 13:30 PT/16:30 ET per discutere i risultati. Gli investitori potranno accedere alla chiamata tramite preregistrazione e seguire la diretta webcast nella sezione Investitori del sito web aziendale di Halozyme.
Halozyme Therapeutics (NASDAQ: HALO) ha anunciado que publicará sus resultados financieros y operativos del primer trimestre de 2025 el martes 6 de mayo de 2025, después del cierre del mercado. La compañía realizará una conferencia telefónica ese mismo día a la 1:30 p.m. PT/4:30 p.m. ET para analizar los resultados. Los inversores pueden acceder a la llamada mediante preregistro y seguir la transmisión en vivo a través de la sección de Inversores del sitio web corporativo de Halozyme.
Halozyme Therapeutics (NASDAQ: HALO)는 2025년 5월 6일 화요일 시장 마감 후 2025년 1분기 재무 및 운영 실적을 발표할 예정입니다. 같은 날 오후 1시 30분 PT/오후 4시 30분 ET에 실적에 대해 논의하는 컨퍼런스 콜을 진행합니다. 투자자들은 사전 등록을 통해 통화에 참여할 수 있으며, Halozyme 기업 웹사이트의 투자자 섹션에서 실시간 웹캐스트를 시청할 수 있습니다.
Halozyme Therapeutics (NASDAQ : HALO) a annoncé qu'elle publiera ses résultats financiers et opérationnels du premier trimestre 2025 le mardi 6 mai 2025, après la clôture des marchés. La société organisera une conférence téléphonique le même jour à 13h30 PT/16h30 ET pour discuter des résultats. Les investisseurs pourront accéder à l'appel via une préinscription et suivre la diffusion en direct dans la section Investisseurs du site web corporate de Halozyme.
Halozyme Therapeutics (NASDAQ: HALO) hat angekündigt, dass es am Dienstag, den 6. Mai 2025, nach Börsenschluss die Finanz- und Betriebsergebnisse für das erste Quartal 2025 veröffentlichen wird. Das Unternehmen wird am selben Tag um 13:30 Uhr PT/16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Investoren können über eine Voranmeldung an dem Anruf teilnehmen und die Live-Webcast über den Investor-Bereich der Unternehmenswebsite von Halozyme verfolgen.
- None.
- None.
Halozyme will host a conference call on Tuesday, May 6, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I7813723.
A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in
For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-333-7668
tbui@halozyme.com
Samantha Gaspar
Teneo
212-886-9356
samantha.gaspar@teneo.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-report-first-quarter-2025-financial-and-operating-results-302439254.html
SOURCE Halozyme Therapeutics, Inc.
FAQ
When will Halozyme (HALO) release Q1 2025 earnings?
How can investors join Halozyme's Q1 2025 earnings call?
What time is Halozyme's Q1 2025 earnings call?
Where can I find the replay of Halozyme's Q1 2025 earnings call?
